Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|6|753-762

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.6, 2018-03, pp. : 753-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antitumor necrosis α treatment in primary sclerosing cholangitis associated inflammatory bowel disease after liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1455-1456

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 10, 2015-05 ,pp. : 980-990

John Wiley & Sons Inc

Access to resources Recommend Favorite

Asynchronous Replication in Lymphocytes from Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

By  

Cytogenetic and Genome Research, Vol. 145, Iss. 1, 2015-04 ,pp. : 35-41

Karger

Access to resources Recommend Favorite

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 3, 2018-03 ,pp. : 532-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: vedolizumab as a treatment and cause of extra‐intestinal manifestations of inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 535-536

John Wiley & Sons Inc

Access to resources Recommend Favorite